Publications and Presentations

Filter By:

Binimetinib

05/31/2014

American Society of Clinical Oncology Meeting

A Phase 1b Open-Label, Multicenter, Dose-Escalation and -Expansion Study of Orally Administered Binimetinib (MEK162) Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

D. Juric, et al.

Binimetinib

05/31/2014

American Society of Clinical Oncology Meeting

A Multinational, Randomized, Open-label Phase 3 Study of Binimetinib (MEK162) versus Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum

B. J. Monk, et al.

Binimetinib

05/30/2014

American Society of Clinical Oncology Meeting

A Phase II Cluster Study of Single-agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

Q. Zhou, et. al

Encorafenib

04/11/2014

HemOnc Today: Melanoma and Cutaneous Malignancies, April 11-12, 2014, New York, NY

The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma

R. Dummer, et. al

ARRY-502

03/01/2014

American Academy of Allergy, Asthma & Immunology Annual Meeting

Safety and Efficacy of ARRY-502, a Potent, Selective, Oral CRTh2 Antagonist, in Patients with Mild to Moderate Th2-Driven Asthma

S. Wenzel, et al.

Filanesib

12/09/2013

American Society of Hematology Annual Meeting

Prolonged Survival and Improved Response Rates with ARRY-520 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with Low Alpha-1 Acid Glycoprotein (AAG) Levels: Results from a Phase 2 Study

S. Lonial, M.D. et al.

ARRY-614

12/09/2013

American Society of Hematology Annual Meeting

Phase 1 Dose-Escalation/Expansion Study of ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes

G. Garcia-Manero, et al.

Filanesib

12/08/2013

American Society of Hematology Annual Meeting

ARRY-520 Combined with Pomalidomide Displays Enhanced Anti-Tumor Activity in Preclinical Models of Multiple Myeloma

M. J. Humphries, et al.

Filanesib

12/07/2013

American Society of Hematology Annual Meeting

Phase I Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib (ARRY-520) + Carfilzomib (Car) in Patients with Relapsed and/or Refractory Multiple Myeloma

J.J. Shah, MD, et al.

Filanesib

12/07/2013

American Society of Hematology Annual Meeting

A Phase 1 Study of ARRY-520 (Filanesib) with Bortezomib in Relapsed or Refractory Multiple Myeloma

A. Chari, et al.